Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

PHF19 inhibition increases IMiDs sensitivity by epigenetically regulating IRF4 and MYC in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

XZXiaoyu ZhangLQLugui Qiu

Discussion

Loading...

Member takes

Overview

RNA sequencing analysis shows PHF19 targeting improves IMiD sensitivity in multiple myeloma, suggesting new therapeutic approaches.

Key Points

  • Inhibition of PHF19 significantly enhances sensitivity to IMiDs in multiple myeloma cells, highlighting its role in drug resistance.
  • RNA-seq revealed dysregulation of IRF4 and MYC pathways linked to PHF19 knockdown, impacting cell cycle and apoptosis.
  • Integrated RNA-seq/ATAC-seq indicates PHF19 regulates chromatin accessibility and mRNA stability of key oncogenes.
  • Targeting the PHF19-IRF4-MYC axis may provide new strategies to tackle multiple myeloma therapy resistance.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db83https://doi.org/10.1182/blood-2025-2164
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immunomodulatory drugs rewire mTORC1-dependent pathways in multiple myeloma to trigger cytotoxicity and immunogenic cell death2025
  2. 2Novel Autoregulation of PIM2 Expression Sustains Plasma Cell Survival in Multiple Myeloma 29162025
  3. 3All-trans retinoic acid and RARβ agonists enhance the efficacy of IMiD-based treatments for t(4;14) multiple myeloma2025
  4. 4CXXC1 is required for IRF4 chromatin binding and expression and regulates cellular fitness in lenalidomide-sensitive and -resistant myeloma cells2025
  5. 5Targeting RNA polymerase I to boost natural killer cell anticancer activity in multiple myeloma2025